Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Influenza Vaccines — United States, 2014–15 Influenza Season*

TABLE 1. Influenza Vaccines — United States, 2014–15 Influenza Season*

Vaccine

Trade name

Manufacturer

Presentation

Mercury content from thimerosal
(µg Hg/0.5 mL)

Ovalbulmin content
(μg/0.5 mL)

Age indications

Route

Inactivated Influenza Vaccine, Quadrivalent (IIV4), Standard Dose

Fluarix® Quadrivalent

GlaxoSmithKline

0.5 mL single-dose prefilled syringe

≤0.05

≥3 yrs.

IM

FluLaval® Quadrivalent

ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)

0.5 mL single-dose prefilled syringe

≤0.3

≥3 yrs

IM

5.0 mL multidose vial

<25

≤0.3

≥3 yrs

IM

Fluzone® Quadrivalent

Sanofi Pasteur

0.25 mL single-dose prefilled syringe

****

6-35 mos.

IM

0.5 mL single-dose prefilled syringe

****

≥36 mos.

IM

0.5 mL single-dose vial

****

≥36 mos.

IM

5.0 mL multidose vial

25

****

≥6 mos.

IM

Inactivated Influenza Vaccine, Trivalent (IIV3), Standard Dose

Afluria®

bioCSL

0.5 mL single-dose prefilled syringe

<1

≥9 yrs.†††

IM

5.0 mL multidose vial

24.5

<1

≥9 yrs.†††

IM

Fluarix®

GlaxoSmithKline

0.5 mL single-dose prefilled syringe

≤0.05

≥3 yrs.

IM

FluLaval®

ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)

0.5 mL single-dose prefilled syringe

≤0.3

≥3 yrs

IM

5.0 mL multidose vial

≤25

≤0.3

≥3 yrs

IM

Fluvirin®

Novartis Vaccines and Diagnostics

0.5 mL single-dose prefilled syringe

≤1

≤1

≥4 yrs.

IM

5.0 mL multidose vial

25

≤1

≥4 yrs.

IM

Fluzone®

Sanofi Pasteur

0.5 mL single-dose prefilled syringe

****

≥36 mos.

IM

5.0 mL multidose vial

25

****

≥6 mos.

IM

Fluzone® Intradermal§

Sanofi Pasteur

0.1 mL prefilled microinjection system

****

18-64 yrs.

ID**

Inactivated Influenza Vaccine, Trivalent, Standard Dose, Cell Culture-based (ccllV3)

Flucelvax®

Novartis Vaccines and Diagnostics

0.5 mL single-dose prefilled syringe

†††

≥18 yrs.†††

IM

Inactivated Influenza Vaccine, Trivalent (IIV3), High Dose**

Fluzone® High-Dose††

Sanofi Pasteur

0.5 mL single-dose prefilled syringe

****

≥65 yrs.

IM

Recombinant Influenza Vaccine, Trivalent (RIV3)

FluBlok®

Protein Sciences

0.5 mL single-dose vial

0

18-49 yrs.

IM

Live-attenuated Influenza Vaccine, Quadrivalent (LAIV4)

FluMist® Quadrivalent§§

MedImmune

0.2 mL prefilled intranasal sprayer

≤0.24 (per 0.2 mL)

2-49 yrs.

IN

Abbreviations: IM = intramuscular; ID = intradermal; IN = intranasal; ACIP = Advisory Committee on Immunization Practices.

* Immunization providers should check Food and Drug Administration–approved prescribing information for 2014–15 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm.

† For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration can be found in ACIP's General Recommendations on Immunization (available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm).

§ Trivalent inactivated vaccine, intradermal: A 0.1-mL dose contains 9 µg of each vaccine antigen (27 µg total).

** The preferred site is over the deltoid muscle. Fluzone Intradermal is administered using the delivery system included with the vaccine.

†† Trivalent inactivated vaccine, high-dose: A 0.5-mL dose contains 60 µg of each vaccine antigen (180 µg total).

§§ FluMist is shipped refrigerated and stored in the refrigerator at 35°F–46°F (2°C–8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Health care providers should consult the medical record, when available, to identify children aged 2 through 4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2 through 4 years should be asked, "In the past 12 months, has a health care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist.

*** Age indication per package insert is ≥5 years; however, ACIP recommends Afluria not be used in children aged 6 months through 8 years because of increased risk for febrile reactions noted in this age group with bioCSL's 2010 Southern Hemisphere IIV3. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years.

††† Information not included in package insert. Estimated to contain <50 femtograms (5x10-8 µg) of total egg protein (of which ovalbumin is a fraction) per 0.5 mL dose of Flucelvax.

§§§ Available upon request from Sanofi Pasteur (telephone: 1-800-822-2463; e-mail: mis.emails@sanofipasteur.com).

Top